Mission Statement, Vision, & Core Values of Coherus BioSciences, Inc. (CHRS)

Ever wondered what drives a biopharmaceutical company focused on oncology? What are the guiding principles behind Coherus BioSciences, Inc. (CHRS), especially as they navigate a transforming landscape with a 4% increase in annual net revenue reaching $267.0 million in 2024 despite significant divestitures?

Understanding a company's mission, vision, and core values provides insight into its strategic direction and corporate culture. How do these elements shape Coherus BioSciences' approach to developing and marketing innovative immunotherapies, and how do they influence their financial decisions, such as the divestiture of UDENYCA® for up to $558.4 million?

Dive in to explore the mission, vision, and core values that steer Coherus BioSciences (CHRS), and discover how these principles align with their strategic goals and recent financial performance, including a 62% year-over-year increase in UDENYCA's net revenue, reaching $206.0 million for the full year 2024.

Coherus BioSciences, Inc. (CHRS) An Overview of

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. As of April 2025, Coherus BioSciences specializes in developing and commercializing biosimilar and innovative medicines. Coherus's portfolio includes:

• Biosimilars: These are follow-on versions of original, branded biologic drugs whose patents have expired.
• Innovative Medicines: Coherus also develops its own novel therapies, often focused on immuno-oncology.

To explore more about the company's background, consider reading this resource: Coherus BioSciences, Inc. (CHRS): History, Ownership, Mission, How It Works & Makes Money

Coherus BioSciences, Inc. reported strong financial results for the year 2024. The company's total net revenue for 2024 was $265.1 million, with $43.5 million in the fourth quarter. UDENYCA net revenue was $65.6 million for the full year and $14.0 million for the fourth quarter of 2024. The company also reported strong performance from LOQTORZI, with $71.5 million in net sales for the year and $21.4 million for the fourth quarter. Additionally, YUSIMRY generated $110.9 million in net revenue for the year and $8.1 million for the fourth quarter of 2024.

Coherus BioSciences is establishing itself as a key player in the biopharmaceutical industry through its focus on biosimilars and innovative medicines. The company's financial performance reflects its strategic focus and execution in key markets, positioning it for continued growth and innovation. Delve deeper to discover the factors driving Coherus's success.

Coherus BioSciences, Inc. (CHRS) Mission Statement

Coherus BioSciences, Inc. is a biopharmaceutical company committed to delivering innovative biopharmaceutical solutions that address critical medical needs. The company's mission is centered around developing and commercializing biosimilar and innovative biologic therapies, with a focus on oncology and immunology.

Coherus's mission is driven by a purpose-driven approach to improve and extend the lives of patients dealing with life-altering diseases. The company's dedication is evident in every decision, milestone, and challenge, with the well-being of patients always at the forefront.

Coherus started with a vision to provide the highest quality biosimilar treatments to patients, expand access to important, cost-effective medicines, and deliver significant savings to the U.S. healthcare system. Since its launch in 2010, Coherus has saved the United States healthcare system over $2 billion, with $1.5 billion in annual savings to the market overall.

A deeper look into Coherus BioSciences, Inc. (CHRS) financial health can be found here: Breaking Down Coherus BioSciences, Inc. (CHRS) Financial Health: Key Insights for Investors

Core Components of the Mission Statement

Coherus BioSciences, Inc.'s mission statement is composed of several core elements that define the company's strategic objectives and operational priorities:

• Innovative Biotechnology Development: Coherus BioSciences demonstrates commitment through specific metrics:
  • R&D Investment: $78.3 million
  • Active Clinical Trials: 7 ongoing programs
  • Patent Portfolio: 23 approved patents
• Strategic Focus Areas:
  • Oncology therapeutic development
  • Immunology treatment innovations
  • Biosimilar product portfolio expansion
• Product Development Strategy:
  • Targeted therapeutic interventions

Vision

Coherus BioSciences envisions expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. health care system.

Core Values

Coherus BioSciences' core values are an intrinsic part of who they are as a company. They are relentless in their pursuit of excellence, but they have each other's backs. They take responsibility for the work, regardless of the outcome and they are thoughtful about how they get there. This balance of risk-taking married with their strong work ethic has created an environment where their employees thrive.

Coherus BioSciences' core values include:

• Integrity: Conducting themselves with honesty, transparency, and ethical behavior in all aspects of their work.
• Innovation: Focused on advancing a diversified portfolio of next-generation immuno-oncology therapies to transform cancer treatment and extend survival for patients with hard-to-treat tumors.
• Performance Driven, Results Oriented to Deliver Organizational Value
• Balanced and Thoughtful Decision-Making
• Team Focused: They thrive on the strength and power of their teams, with each team member working issues through the team. They interact in an objective, respectful way, depersonalizing and objectifying conflicts or issues. They value an outgoing, friendly, participative demeanor coupled with strong convictions and a lack of self-interest, and do not tolerate politics, personal agendas or accommodate ego needs. Such behavior is highly penalized.
• Willingness to Take Risk, Responsibility and Demonstrate Initiative

Coherus BioSciences, Inc. (CHRS) Vision Statement of

Coherus BioSciences, Inc. operates with a clear vision focused on transforming the lives of cancer patients. This vision is supported by a mission to provide access to high-quality, cost-effective biosimilars and innovative immuno-oncology therapeutics. As of April 2025, the company's strategic goals and financial performance reflect its dedication to this vision.

Mission Statement: Expanding Access to Cancer Therapies

Coherus BioSciences' mission is centered on making cancer treatments more accessible and affordable. This involves developing and commercializing biosimilars, which are similar to existing branded biologic drugs but offered at a lower cost. The company also invests in innovative immuno-oncology therapies, aiming to improve patient outcomes through novel treatments. In 2024, Coherus reported revenues of $272.4 million, with biosimilar revenues contributing significantly to this total. This financial performance underscores the company's ability to execute its mission of providing cost-effective alternatives and expanding treatment options for patients.

Key aspects of their mission include:

• Developing Biosimilars: Creating affordable versions of complex biologic drugs to increase access for patients.
• Investing in Innovation: Focusing on novel immuno-oncology therapies to improve treatment outcomes.
• Commercial Excellence: Effectively marketing and distributing their products to reach a broad patient base.

Vision: A Leader in Cancer Care

The overarching vision of Coherus BioSciences is to become a recognized leader in cancer care. This involves not only providing affordable treatment options but also pioneering new therapies that can significantly improve the lives of cancer patients. The company's strategic initiatives, such as the acquisition ofSurface Oncology in 2023 for an upfront payment of $52.7 million, demonstrate a commitment to expanding its portfolio of innovative cancer treatments. As of 2024, Coherus had research and development expenses of $133.5 million, reflecting its investment in future growth and innovation. This financial commitment supports the long-term vision of becoming a leader in the oncology space.

Core Values: Guiding Principles

Coherus BioSciences operates on a foundation of core values that guide its actions and decisions. These values include:

• Integrity: Maintaining the highest ethical standards in all aspects of the business.
• Innovation: Continuously seeking new and better ways to treat cancer.
• Collaboration: Working together with partners and stakeholders to achieve common goals.
• Patient-Centricity: Focusing on the needs of patients and ensuring they have access to the best possible care.

These values are reflected in the company's commitment to quality, safety, and affordability in its products. For example, Coherus has implemented rigorous quality control processes to ensure that its biosimilars meet the same standards as the original biologic drugs. The company also works closely with patient advocacy groups to understand the needs of cancer patients and develop programs that support their access to treatment.

For more insights into Coherus BioSciences, Inc., explore: Coherus BioSciences, Inc. (CHRS): History, Ownership, Mission, How It Works & Makes Money

Coherus BioSciences, Inc. (CHRS) Core Values of

Coherus BioSciences, Inc. operates with a defined set of core values that guide its actions and decisions. While specific, publicly detailed core values can sometimes be limited, we can infer key principles from their publicly stated goals, actions, and overall mission. These inferred values reflect what the company prioritizes in its operations and interactions. For additional background, you might find this resource helpful: Coherus BioSciences, Inc. (CHRS): History, Ownership, Mission, How It Works & Makes Money

Commitment to Innovation

A dedication to innovation is crucial for a biotechnology company like Coherus. This commitment likely manifests in their approach to developing and commercializing biosimilars and novel therapies. Evidenced by their pipeline and strategic focus, innovation is likely a driving force.

• Focus on expanding access to high-quality medicines through biosimilars.
• Investment in research and development for novel immuno-oncology therapeutics.

Integrity and Quality

In the pharmaceutical industry, maintaining the highest standards of integrity and quality is paramount. This value ensures that their products are safe, effective, and reliable for patients. Coherus likely emphasizes rigorous testing, compliance, and ethical conduct throughout its operations.

• Adherence to strict regulatory guidelines and quality control measures.
• Ethical conduct in clinical trials and commercial practices.

Patient-Centric Approach

Focusing on the needs of patients is central to any healthcare company's mission. A patient-centric approach means Coherus likely prioritizes making treatments accessible and affordable while addressing unmet medical needs. This value is reflected in their efforts to provide cost-effective alternatives to expensive branded drugs.

• Programs aimed at improving patient access to biosimilars.
• Efforts to address unmet medical needs in specific therapeutic areas.

Collaboration and Partnership

Collaboration is essential for success in the complex and competitive biotechnology landscape. This value suggests that Coherus actively seeks partnerships and alliances to enhance its capabilities and expand its reach. These collaborations can range from research collaborations to commercial partnerships.

• Strategic alliances with other pharmaceutical companies and research institutions.
• Collaborative efforts to develop and commercialize new therapies.

Accountability and Transparency

Operating with accountability and transparency builds trust with stakeholders, including investors, healthcare professionals, and patients. This value implies that Coherus is committed to open communication, responsible decision-making, and ethical governance.

• Transparent reporting of clinical trial results and financial performance.
• Accountable leadership and corporate governance practices.